Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.

Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T

Open source

DOI: 10.1038/s41416-023-02212-2
Published: 2023 May
Container: British journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41416-023-02212-2,
  title = {Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.},
  author = {Kuboki Y and Terazawa T and Masuishi T and Nakamura M and Watanabe J and Ojima H and Makiyama A and Kotaka M and Hara H and Kagawa Y and Sugimoto N and Kawakami H and Takashima A and Kajiwara T and Oki E and Sunakawa Y and Ishihara S and Taniguchi H and Nakajima TE and Morita S and Shirao K and Takenaka N and Ozawa D and Yoshino T},
  year = {2023},
  journal = {British journal of cancer},
  doi = {10.1038/s41416-023-02212-2},
  url = {https://doi.org/10.1038/s41416-023-02212-2}
}

RIS

TY  - JOUR
TI  - Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
AU  - Kuboki Y
AU  - Terazawa T
AU  - Masuishi T
AU  - Nakamura M
AU  - Watanabe J
AU  - Ojima H
AU  - Makiyama A
AU  - Kotaka M
AU  - Hara H
AU  - Kagawa Y
AU  - Sugimoto N
AU  - Kawakami H
AU  - Takashima A
AU  - Kajiwara T
AU  - Oki E
AU  - Sunakawa Y
AU  - Ishihara S
AU  - Taniguchi H
AU  - Nakajima TE
AU  - Morita S
AU  - Shirao K
AU  - Takenaka N
AU  - Ozawa D
AU  - Yoshino T
PY  - 2023
JO  - British journal of cancer
DO  - 10.1038/s41416-023-02212-2
UR  - https://doi.org/10.1038/s41416-023-02212-2
ER  -

APA

Y, K., T, T., T, M., M, N., J, W., H, O., A, M., M, K., H, H., Y, K., N, S., H, K., A, T., T, K., E, O., Y, S., S, I., H, T., TE, N., S, M., K, S., N, T., D, O., & T, Y. (2023). Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.. British journal of cancer. https://doi.org/10.1038/s41416-023-02212-2

Source records

pubmed · retrieved 2026-09-27T13:11:37.491Z